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Abstract
Continuous erythropoietin receptor activator (CERA) is a third-generation
erythropoiesis-stimulating agent that was developed for the treatment of anemia.
However, misuse of CERA for doping in endurance sports has been reported.
Previous studies have shown blood as the matrix of choice for the detection of
CERA, due to its high molecular weight. The use of dried blood spots (DBSs) for
anti-doping purposes constitutes a complementary approach to the standard urine
and venous blood matrices and could facilitate sample collection and increase the
number of blood samples available for analysis due to reduced costs of sample collec-
tion and transport. Here, we investigated whether CERA could be indirectly detected
in extracts of single DBSs using an erythropoietin-specific immunoassay that is capa-
ble of providing results within approximately 2 h. Reconstituted DBS samples were
prepared from mixtures of red blood cell pellets and serum samples. The samples
were collected in a previous clinical study in which six healthy volunteers were
injected with a single, 200 μg dose of CERA. Using a commercially available ELISA kit,
CERA was detected in the DBSs with a detection window of up to 20 days post-
injection. Furthermore, in order to demonstrate the fitness-for-purpose, three
authentic doping control serum samples, which were identified as containing CERA,
were analyzed by the presented methodological approach on DBS. The testing
procedure described here could be used as a fast and cost-effective method for the
detection of CERA abuse in sport.
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1 | INTRODUCTION
Use of erythropoietin receptor agonists (ERAs)) for performance-
enhancing purposes can be detected via direct and indirect methods.1
Direct detection typically relies on separation techniques that depend
on the isoelectric point (IEF method) or molecular weight (e.g., sodium
N-lauroylsarcosinate polyacrylamide gel electrophoresis [SAR-PAGE]
or SDS-PAGE) of the ESA.1,2
The pharmaceutical industry has developed recombinant human
EPO (rhEPO) for therapeutic purposes.3 Epoetin alfa was the first
rhEPO to become commercially available. The bioavailability of
epoetin alfa is low, and up to three injections per week are needed to
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attain therapeutic effects.4 For doping, the short elimination time is
advantageous, because the detection window is narrowed, whereas
the effect is sustained. For this reason, the first generation rhEPO is
the most used by cheated athletes. The optimal matrix to detect first
generation of rhEPO is urine.5 Continuous erythropoietin receptor
activator (CERA) also known as the drug MIRCERA® is a third-
generation ESA in which rhEPO is linked to a polyethylene glycol
group. Compared with rhEPO, CERA has a lower affinity for the EPO
receptor and a longer serum half-life.6 In addition, the polyethylene
glycol chain diminishes the renal filtration and elimination of CERA,
making blood a more suitable matrix for its detection than urine.7,8
The slow elimination time and long detection window may suggest
that CERA is not the first choice of rhEPO for doping purposes.
Nevertheless, recent anti-doping operations have demonstrated that
doping practices with CERA is still relevant scenario in endurance
sport.8,9 These findings indicate that doping is widespread in athletes
competing regionally and that CERA is still a popular drug for
endurance sports. They underline the need to facilitate blood
sampling during nonmajor competitions.
Dried blood spots (DBSs) are convenient matrices for the analysis
of blood samples. They are typically produced via a finger prick,10,11
from where a drop of blood is collected onto a paper card. DBSs offer
a number of advantages over conventional blood sample draw, includ-
ing ease of collection by nonspecialized personnel, low invasiveness,
reduced cost of analysis, facilitated transportation, easy storage, and
high stability of analytes.12 Furthermore, previous studies have dem-
onstrated a promising applicability and sufficient sensitivity of DBSs
for the detection of a wide range of doping substances.13–16 Recently,
Reverter-Branchat et al.17 described the methodology established for
the monitoring of CERA in DBS by western-blotting methods. These
results support the concept of DBS-based CERA testing in blood
samples of elite athletes.
The aim of our current study was to determine if CERA can be
detected in DBSs using a simple enzyme-linked immunosorbent assay
(ELISA). For this purpose, DBSs were generated from serum samples
collected during a pilot study in which six healthy volunteers received
a single intravenous injection of CERA (200 μg).
2 | MATERIALS AND METHODS
2.1 | DBS preparation
This study used serum samples collected during a pilot excretion study
performed by Lamon et al.,18 in which six healthy volunteers received
a single intravenous injection of 200 μg CERA (MIRCERA®, Roche
Pharma AG) and which was approved by the local ethical committee
(protocol #05/08). The volunteers were Caucasian men aged
20–28 years, with a mean body mass index of 23.3 kg/m2
(SD 1.48 kg/m2). None of the volunteers was involved in elite sport.
Blood samples were collected every morning over the first 4 post-
administration days. Thereafter, blood sampling was performed on
days 6, 8, 10, 13, 16, 20, and 24. For four of the subjects, blood was
also collected on day 27 post-injection (Figure 1). Venous blood was
collected from the elbow crease into EDTA tubes from heathy volun-
teers. After centrifugation at 300g for 10 min, the erythrocytes were
isolated and washed twice with hypotonic solution (0.9% NaCl)
and then mixed gently with an appropriate serum (50:50 ratio) as
described by Reverter-Branchat et al.17 Subsequently, 20-μl aliquots
of this modeled blood were spotted onto the DBS card (Whatman
903™ filter paper cards). The cards were left to dry for a minimum of
1 hour, and then the cards were stored at room temperature in sealed
plastic bags until analysis. Same procedure was used for reconstituted
volumetric absorptive microsampling (VAMS) (Neoteryx™).
2.2 | DBS and VAMS extraction
For extraction, an entire blood spot of 20 μl was punched out of the
DBS card manually and transferred to a 2-ml Eppendorf tube. Alterna-
tively the polymeric extremity of the VAMS with 20-μl dried blood
was directly put in a 2-ml tube. Extraction buffer (1% Tween in 1-ml
H2O) was then added, and the sample was incubated for 15 min in a
thermoshaker at 450 rpm and 37C. Subsequently, the tube was cen-
trifuged briefly and placed in a sonicator for 15 min. After sonication,
the tube processed in the thermoshaker for another cycle of 15 min.
2.3 | Immunoassays
ELISA assays from StemCell™ Technologies and R&D Systems were
performed as described in manufacturer's instructions. Briefly, 100 μl
of extracted DBS was added to the ELISA plate and detected by
absorbance.
3 | RESULTS
3.1 | Quantification of EPO in DBSs using
immunoassays
Immunoassays were used to determine the concentration of EPO in
DBSs generated from serum samples collected from six volunteers
after administration of a single dose (200 μg) of CERA. Blood samples
were collected for up to 27 days (D0–D27, where D0 represents the
day of administration; Figure 1). The cut-off limit representing an
abnormal concentration of EPO was 1.74 mIU/ml (14.62 pg/ml), as
determined using the mean + 2SD value in serum samples from an
unexposed to CERA population (n = 80) as described in Lamon
et al.18
First, we used an ELISA kit from StemCell™ Technologies to
detect EPO in the DBS samples. In this assay, the EPO concentration
in the DBSs was observed to increase in all subjects following the
CERA injection. Nevertheless, inter-individual differences were signifi-
cant as the detection time of EPO above the cut-off limit ranged from
three (subject 4) to 20 days (subject 6), the calculated mean being
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approximately 11 days (Figure 2A and Table 1). The overall dynamic
trend of the changes in the levels of EPO in the DBSs was comparable
to that of the level of CERA in the original serum samples from which
the DBSs were generated.18 In addition, the concentrations of EPO in
the DBSs and CERA in the original serum samples18 were highly
correlated (Pearson's correlation coefficient: R = 0.9301, p < 0.001)
(Figure 2B).
For assay comparison, we measured the EPO concentrations
in the DBSs using an ELISA kit from R&D Systems. Significant
intra-assay variation was observed regarding specificity, as the
post-injection concentrations of EPO detected using this kit were
not consistent with the results obtained using the ELISA kit from
StemCell™ Technologies. Moreover, a Pearson's correlation analysis
did not show any association between the serum concentrations of
CERA detected previously18 and the levels of EPO in the DBS sam-
ples detected using the R&D Systems kit (R = 0.02143, p > 0.05)
(Figure 2D).
In order to study the fitness-for-purpose of the presented DBS
approach, three serum samples (A, F, and G) were reconstituted from
authentic doping control serum samples confirmed previously by IEF
and SDS-PAGE to contain CERA.8 These samples were screened
using the StemCell™ Technologies kit. Analysis using the StemCell™
Technologies ELISA kit revealed that the concentrations of EPO in
samples A, F, and G were higher than the cut-off limit established
previously (1.72 mUI/ml;14.62 pg/ml) (Figure 3). Similar results were
obtained with reconstituted VAMS (Figure 3).
F IGURE 2 The concentrations of EPO in the DBS samples, as measured using two different EPO ELISA kits. (A) EPO concentrations
measured using the EPO ELISA kit from StemCell™ technologies. (B) Pearson's correlation between the CERA concentration in serum (ng/ml)14 in
DBSs (mIU/ml) by StemCell™ kit. (C) EPO concentrations by Quantikine IVD ELISA kit. (D) Pearson's correlation between the CERA concentration
in serum (ng/ml)14 and the EPO concentration in DBSs (mIU/ml) measured using the human erythropoietin Quantikine IVD ELISA kit. In (a) and
(C), the dashed red line represents the abnormal level cut-off limit (1.74 mIU/ml, 14.62 pg/ml) [Colour figure can be viewed at wileyonlinelibrary.
com]
F IGURE 1 Experimental design of the CERA study. Volunteers were injected with a single 200 μg dose of CERA (MIRCERA®) on day 0 (D0).
The red dots represent venous blood collection on post-injection D1 through D27 [Colour figure can be viewed at wileyonlinelibrary.com]
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4 | DISCUSSION
Here, we describe the indirect detection of CERA in reconstituted
DBSs using an EPO-specific immunoassay (ELISA kit from StemCell™
Technologies), after a single injection of six volunteers with 200 μg
CERA. Reassuringly, the dynamic trend of changes in the EPO concen-
tration in the DBSs was similar to that of the CERA level in the
original serum samples.18 In addition, there was a significant correla-
tion (R = 0.9301, p < 0.05) between the EPO levels in the DBSs and
the CERA levels in the serum samples. These findings suggest that
DBSs could represent a potential alternative matrix for the initial test-
ing of CERA for anti-doping purposes.
In an earlier study, measurement of the endogenous EPO level
in a negative control population has allowed for setting a cut-off
limit that was proposed as a threshold of EPO, below which sam-
ples would be considered negative (for doping). This limit, which
was set as the mean value of the unexposed population plus 2SD,
equated to 1.74 mIU/ml (14.62 pg/ml). The World Anti-Doping
Agency has recently set 25 pg/ml as the minimum required perfor-
mance level for the detection of CERA in serum.19 Based on these
preliminary results, the now described method complies with the
criteria and shows approximately twice the sensitivity to detect
EPO in DBS samples. Here, we used the determined cut-off limit to
establish the window of detection of EPO in each DBS sample. The
window for CERA detection varied between the six subjects: the
shortest detection time was until D3 after CERA injection (subject
4), whereas the longest prevailed until day D20 (subject 6). The
earlier-presented choice of mean + 2SD was made to achieve 95%
confidence interval for assay specificity. Limited but existing risk of
false suspicious can be considered acceptable, as the initial testing
procedure is aimed at high sensitivity and whereas the non-
compromised specificity is assured at secondary stage by the confir-
mation method(s).
Our findings suggest that the detection of CERA in DBSs can be
achieved using a specific EPO immunoassay. Primary screening of
DBSs using this method could be used to provide preliminary informa-
tion on the presence of CERA. Further investigations, such as western
blot analyses, are needed for confirmation analysis of samples that
exceed the EPO quantification cut-off limit. The western-blotting
with DBS could be performed as already described by Reverter-
Branchat.17
Our exercise demonstrated the importance of assay selection, as
the inter-assay differences could be significant regarding the specific-
ity for CERA. In addition to the ELISA kit from StemCell™ Technolo-
gies, we also attempted to measure the EPO concentration in DBSs
using a specific immunoassay kit from R&D Systems. The results
obtained with this kit were not consistent with those obtained using
the kit from StemCell™ Technologies. In addition, they were not
TABLE 1 Detection of abnormal
concentrations of EPO in DBSs from
each subject after injection of 200 μg
CERA
ID D0 D1–D3 D4 D6 D8 D10 D13 D16 D20 D24 D27
S1  + + + + + +    
S2  + + + + + + +   
S3  + + + +     
S4  +        
S5  + + + +      
S6  + + + + + + + +  
Note. Day 0 (D0) represents the day of injection. The + and – symbols represent concentrations of EPO
that were higher or lower than the cut-off limit (1.74 mIU/ml, 14.62 pg/ml), respectively. For subjects 3
and 4, the sampling stopped at D24.
F IGURE 3 Analyses of EPO/CERA in DBSs
generated from athletes serum samples. The
serum samples tested (a, F, and G) were collected
from elite subjects who tested positive for
abnormal levels of CERA with SAR-PAGE. EPO
concentrations in DBSs (black) and VAMS (grey),
as measured using the EPO ELISA kit from
StemCell™ technologies. The dashed red line
represents the abnormal level cut-off limit
(1.74 mIU/ml, 14.62 pg/ml) [Colour figure can be
viewed at wileyonlinelibrary.com]
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consistent with the CERA concentrations reported in the serum sam-
ples from which the DBSs were generated.18
DBS comparatively to starting from higher volumes of blood will
logically be less sensitive with a potential risk of false negative
for CERA.
WADA Guidelines recommend starting from 500 μl of serum to
detect 25 pg/ml (MRPL) while these presented experiments were per-
formed with 25-fold less blood. However, even when starting from
20-μl dried blood, our results indicate robust identification of
14.62 pg/ml. In this line, analysis of the reconstituted DBSs that were
generated from three authentic doping control serum samples had
been earlier observed on IEF/SDS-PAGE to contain CERA. Moreover,
the CERA in serum samples were identified with 1 ml of starting
volume.
DBS testing could be used as a fast (2 h) screening method for
the detection of CERA due to its ease of use over the collection of
venous samples to compare standard western-blotting method last
several days from purification to results interpretation. Due the
prolonged half-life of CERA more frequent testing facilitated by the
collect of DBS instead of venous blood could improve the efficiency
and also deterrence from doping practices.
5 | LIMITATIONS
This pilot study has clearly a number of limitations, which require fur-
ther work prior to application to a routine context. Firstly, the number
of volunteers is limited, and the samples used in the study were
obtained from young Caucasian males who were not involved in elite
sport. Secondly, an intravenous injection of 200-μg MIRCERA® repre-
sents a therapeutic dose. The more probable doping scenario could be
the application of micro-doses that would be much more difficult to
detect. Thirdly, DBS samples from clinical study with volunteers
injected with high dose of Eprex were tested, and we did not observe
significant increase with our method (data not shown). These data
suggest that our strategy does not fit for first generation recombinant
EPOs. Finally, the reconstitution of DBSs results in dilution of the
total amount of CERA in the sample, leading to a probable deviation
from the real serum concentration.
6 | CONCLUSION
In conclusion, a single injection of 200-μg CERA was detectable in
DBS samples using a specific EPO immunoassay. Notably, the specific
ELISA kit used for the analysis influenced the results. The ELISA kit
from StemCell™ Technologies showed good performance, whereas
the specificity of the immunoassay kit from R&D Systems was not fit
for this purpose. Based on our findings, we suggest that an approach
based on immunoassay analysis of DBS samples has a potential to be
developed as a simple and rapid method for a primary screening of
CERA misuse. For this specific use, DBS could be a valuable addition
to urine samples, that will stay the matrix of choice to test the other
rhEPOs but is not ideal for CERA detection. A western blot analysis
would be required for confirmation procedure if the EPO concentra-
tion detected in the immunoassay exceeded a predefined cut-off limit
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